You are here

Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Unidad de Investigación en Salud (UIS)
Chihuahua, , Mexico
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Onychomycosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Witnessed, signed informed consent approved by Ethics Committee

2. Male or female subjects of any race at least 18 years of age but not older than 65
years of age at the time of screening

3. Subjects with a diagnosis of onychomycosis of at least one great toenail and with a
positive KOH wet mount from that nail

4. Onychomycosis involving 20-60% of the affected great toenail as determined by visual
inspection after the nail has been trimmed

5. The combined thickness of the distal nail plate and the associated hyperkeratotic nail
bed

6. Affected great toenail to be treated is capable of re-growth as documented by history
or recent observation of at least 2 mm of growth

7. Normal or not clinically significant screening safety labs

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Females of childbearing potential not using a highly effective method of birth control
(e.g. implants, injectables, combined oral contraceptives, some intrauterine
contraceptive devices) during the study

2. Diabetes mellitus requiring treatment other than diet and exercise

3. Subjects with chronic moccasin type of T. pedis

4. Subjects with a history of having failed any previous topical antifungal therapy for
their onychomycosis

5. Subjects unwilling to refrain from the use of nail cosmetics such as clear and or
colored nail lacquers from the screening visit until the end of the study.

6. Subjects that have not undergone the specified washout period(s) for the following
topical preparations or subjects who require the concurrent use of any of the
following topical medications:

- Topical antifungal applied to the feet (does not include antifungals for
treatment of T. pedis during the study): 4 weeks

- Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks

7. Subjects that have not undergone the specified washout period(s) for the following
systemic medications or subjects who require the concurrent use of any of the
following systemic medications:

- Corticosteroids (including intramuscular injections): 2 weeks

- Antifungals for treatment of onychomycosis or any systemic antifungal with known
activity against dermatophytes: 24 weeks

- Systemic immunomodulators: 4 weeks

8. Treatment of any type for cancer within the last 6 months

9. History of any significant internal disease

10. Subjects with a medical history of current or past psoriasis of the skin and/or nails

11. Concurrent lichen planus

12. Subjects who are known to be allergic to any of the test product(s) or any components
in the test product(s) or history of hypersensitivity or allergic reactions to any of
the study preparations as described in the Investigator's Brochure

13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
disorders, onychogryphosis, trauma to the nail(s) to be treated

14. AIDS or AIDS related complex

15. History of street drug or alcohol abuse

16. Any subject not able to meet the study attendance requirements

17. Subjects who have participated in any other trial of an investigational drug or device
within 60 days prior to enrollment or participation in a research study concurrent
with this study

NCT00679523
Pfizer
Completed
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Onychomycosis
NCT00680095
All Genders
18+
Years
Lynchburg, Virginia
Subungual Onychomycosis Distal
NCT00679965
All Genders
18+
Years
Multiple Sites
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail
The purpose of the study is to determine the safety and efficacy of 5.0% and 7.5% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.
The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and given 5% AN2690 Solution. Provided that there is adequate evidence of clinical safety after two weeks of dosing with 5% AN2690 Solution, a second group of 30 protocol-qualified subjects will be assigned to Treatment Group 2 and given 7.5% AN2690 Solution. A third group of 30 subjects will be enrolled and assigned the highest safe concentration of AN2690 evaluated in this study.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Onychomycosis
  • Drug: AN2690 Solution, 5.0%
    Once daily application for 180 days
  • Drug: AN2690 Solution, 7.5%
    Once daily application for 180 days
  • Experimental: Group 1
    AN2690 Solution, 5.0%
    Intervention: Drug: AN2690 Solution, 5.0%
  • Experimental: Group 2
    AN2690 Solution, 7.5%
    Intervention: Drug: AN2690 Solution, 7.5%
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
February 2007
February 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Witnessed, signed informed consent approved by Ethics Committee
  2. Male or female subjects of any race at least 18 years of age but not older than 65 years of age at the time of screening
  3. Subjects with a diagnosis of onychomycosis of at least one great toenail and with a positive KOH wet mount from that nail
  4. Onychomycosis involving 20-60% of the affected great toenail as determined by visual inspection after the nail has been trimmed
  5. The combined thickness of the distal nail plate and the associated hyperkeratotic nail bed <3 mm
  6. Affected great toenail to be treated is capable of re-growth as documented by history or recent observation of at least 2 mm of growth
  7. Normal or not clinically significant screening safety labs

Exclusion Criteria:

  1. Females of childbearing potential not using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study
  2. Diabetes mellitus requiring treatment other than diet and exercise
  3. Subjects with chronic moccasin type of T. pedis
  4. Subjects with a history of having failed any previous topical antifungal therapy for their onychomycosis
  5. Subjects unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study.
  6. Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications:

    • Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study): 4 weeks
    • Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
  7. Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:

    • Corticosteroids (including intramuscular injections): 2 weeks
    • Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophytes: 24 weeks
    • Systemic immunomodulators: 4 weeks
  8. Treatment of any type for cancer within the last 6 months
  9. History of any significant internal disease
  10. Subjects with a medical history of current or past psoriasis of the skin and/or nails
  11. Concurrent lichen planus
  12. Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
  13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
  14. AIDS or AIDS related complex
  15. History of street drug or alcohol abuse
  16. Any subject not able to meet the study attendance requirements
  17. Subjects who have participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
 
NCT00679523
AN2690-ONYC-201 Cohort 1 & 2
No
Not Provided
Not Provided
Karl Beutner, MD, PhD, Anacor Pharmaceuticals, Inc.
Pfizer
Not Provided
Study Director: Karl Beutner, MD, PhD Pfizer
Pfizer
May 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now